Dr. Hammond’s laboratory studied AAV8 gene transfer carrying urocortin 2 or 3 in normal mice, focusing on effects on left ventricular function and glucose disposal.
Dr. H. Kirk Hammond is the Company’s principal scientific advisor and a cardiologist. He co-founded Collateral Therapeutics and Renova Therapeutics and is a professor at the University of California San Diego and a cardiologist at VA San Diego.
Founded in 2009, Renova Therapeutics is developing gene therapies for cardiovascular and metabolic diseases, including congestive heart failure and type 2 diabetes.
Renova Therapeutics’ privacy policy outlines the personal information and data collected through its websites, how the company uses the data, and why it may share it with third parties.
Renova Therapeutics operates renovatherapeutics.com and other domains that forward to the site, providing information about its products and services. The websites and services are hosted in the United States.